万泰生物上半年净利亏损1.44亿元，同比转亏

Group 1 - The core point of the article is that Wantai Biological (603392) reported a significant decline in revenue and a net loss for the first half of 2025, primarily due to challenges in its vaccine segment [2] - The company achieved an operating revenue of 844 million yuan, representing a year-on-year decrease of 38.25% [2] - The net profit attributable to shareholders was -144 million yuan, indicating a shift from profit to loss compared to the previous year [2] Group 2 - The decline in revenue is attributed to market adjustments, government procurement policies, and the expansion of the age range for the nine-valent HPV vaccine, which led to lower-than-expected sales [2]